Last updated on April 2020

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis


Brief description of study

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 comprising Part 2. All subjects will receive open-label ISB 830 after a 16 week blinded treatment period.

Clinical Study Identifier: NCT03568162

Find a site near you

Start Over

Glenmark Investigational Site 132

Chattanooga, TN United States
  Connect »

Glenmark Investigational Site 103

Newport News, VA United States
  Connect »

Glenmark Investigational Site 116

San Antonio, TX United States
  Connect »

Glenmark Investigational Site 105

Rolling Hills Estates, CA United States
  Connect »

Glenmark Investigational Site 125

West Des Moines, IA United States
  Connect »

Glenmark Investigational Site 102

Forest Hills, NY United States
  Connect »

Glenmark Investigational Site 126

Saint Louis, MO United States
  Connect »

Glenmark Investigational Site 122

Philadelphia, PA United States
  Connect »

Glenmark Investigational Site 118

Santa Monica, CA United States
  Connect »

Glenmark Investigational Site109

New Orleans, LA United States
  Connect »

Premier Clinical Research

Spokane, WA United States
  Connect »

Glenmark Investigational Site 147

Ormond Beach, FL United States
  Connect »

Glenmark Investigational Site 138

Pflugerville, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.